Absorption, distribution, metabolism, and elimination (ADME) of umeclidinium (UMEC) in healthy adults
D. Kelleher, S. Hughes, R. Mehta, L. Tombs, K. Kelly, A. Church (Research Triangle Park, United States Of America; Ware, Slough, Uxbridge, United Kingdom)
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Kelleher, S. Hughes, R. Mehta, L. Tombs, K. Kelly, A. Church (Research Triangle Park, United States Of America; Ware, Slough, Uxbridge, United Kingdom). Absorption, distribution, metabolism, and elimination (ADME) of umeclidinium (UMEC) in healthy adults. Eur Respir J 2012; 40: Suppl. 56, 2153
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
The absorption, distribution, metabolism and excretion (ADME) of single oral doses of AZD5069, a novel CXCR2 antagonist, in healthy male volunteers Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Effect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Safety, pharmacodynamics (PD) and pharmacokinetics (PK) of darotropium (DARO) and vilanterol (VI) in healthy subjects: Two phase 1 studies Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Effect of severe renal impairment (SRI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Absorption, metabolism and excretion of fevipiprant (QAW039) investigated in vivo and in vitro Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016
Absorption behavior of riociguat (BAY 63-2521): Bioavailability, food effects, and dose-proportionality Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
The pharmacokinetics (PK) and pharmacodynamics (PD) of the fluticasone furoate (FF) and vilanterol (VI) combination in subjects with hepatic impairment Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD7594 after single and multiple ascending inhaled doses in healthy Japanese males Source: International Congress 2017 – COPD management Year: 2017
Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy at two UMEC doses in healthy subjects Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014
Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy in healthy subjects Source: International Congress 2014 – Asthma and COPD management Year: 2014
The pharmacokinetics (PK) and pharmacodynamics (PD) of the fluticasone furoate (FF) and vilanterol (VI) combination in subjects with severe renal impairment Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
The effect of ketoconazole on the pharmacokinetics (PK) and pharmacodynamics (PD) of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
The pharmacokinetics (PK) and pharmacodynamics (PD) of repeat inhaled administration of fluticasone furoate (FF) in healthy Caucasian, Chinese, Japanese and Korean subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Pharmacokinetic (PK) interaction of ketoconazole (KC), clarithromycin (CM) and midazolam (MZ) with riociguat Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
Pharmacokinetics (PK) and pharmacodynamics (PD) of tetomilast in stable COPD subjects Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006
Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (320/9mcg) Spiromax® and BF (400/12mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV) Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013
Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (160/4.5mcg) Spiromax® and BF (200/6mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV) Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013
Single-dose, first-in-human study of AMG 853: Pharmacokinetics, pharmacodynamics, and safety in healthy adults Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Pharmacokinetics (PK) of single doses of mometasone furoate (MF) delivered via the Breezhaler® (BH) and Twisthaler® (TH) devices in healthy subjects Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012